Palliative Care in Lung Cancer (All Types): A Comprehensive Clinical Review

 Palliative Care in Lung Cancer (All Types): A Comprehensive Clinical Review

Authors: Dr. Shekhar  and Team, Doctor’s Forum for All 🏥

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Structured Abstract

Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, with most patients presenting at advanced stages where curative intent is no longer feasible. The symptom burden in advanced lung cancer is substantial, including dyspnoea, cough, haemoptysis, pain, fatigue, and psychological distress.

Objective: This review aims to provide a comprehensive, clinically verified framework for palliative care in lung cancer, covering symptom assessment and management, interventional palliative procedures, psychosocial support, advance care planning, and end-of-life care.

Methods: A structured narrative review was conducted using evidence from peer-reviewed guidelines, systematic reviews, randomized controlled trials, and consensus statements. Key sources included the American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), National Institute for Health and Care Excellence (NICE), and Cochrane systematic reviews.

Results: Early integration of palliative care improves quality of life, mood, and possibly survival. Effective symptom management includes opioids for dyspnoea and pain, interventional procedures for airway obstruction and pleural effusion, radiotherapy for haemoptysis and bone metastases, and comprehensive psychosocial support. Advance care planning is essential given the unpredictable trajectory of lung cancer.

Conclusion: Palliative care is an integral component of comprehensive lung cancer management and should be initiated at diagnosis, delivered concurrently with disease-directed therapy, and intensified as the disease progresses. A multidisciplinary, patient-centred approach is essential.

Keywords: Lung cancer, palliative care, dyspnoea, haemoptysis, malignant pleural effusion, advance care planning, end-of-life care.

1. Introduction

Lung cancer is the most commonly diagnosed cancer worldwide (2.2 million new cases annually) and the leading cause of cancer death (1.8 million deaths annually) [1]. Approximately 85% of cases are non-small cell lung cancer (NSCLC), while 15% are small cell lung cancer (SCLC). Most patients present with advanced disease (Stage III–IV) at diagnosis, where the goals of care shift from cure to prolongation of life and symptom control.

Despite advances in targeted therapy, immunotherapy, and precision medicine, the overall 5-year survival for lung cancer remains approximately 20% [1]. The symptom burden is among the highest of all cancers, with patients experiencing multiple concurrent symptoms including dyspnoea (70–90%), cough (50–80%), pain (40–70%), fatigue (80–100%), anorexia (50–70%), and psychological distress (30–50%) [2].

Landmark research has demonstrated that early integration of palliative care with standard oncology care improves quality of life, reduces depression, and may extend survival in patients with metastatic NSCLC [3,4]. This has led to ASCO and NCCN guidelines recommending early palliative care referral for all patients with advanced lung cancer [5,6].

2. Methods

This review was conducted using a structured search of PubMed, Cochrane Library, and clinical guideline databases. Search terms included "palliative care," "lung cancer," "dyspnoea," "haemoptysis," "malignant pleural effusion," "airway obstruction," "advance care planning," and "end-of-life care." Inclusion criteria encompassed systematic reviews, randomized controlled trials, clinical practice guidelines, and consensus statements published in English between 2000 and 2026. Key guidelines consulted included ASCO [5], NCCN [6], NICE [7], and the American College of Chest Physicians (ACCP) [8].

3. Results

3.1 Early Integration of Palliative Care

The landmark randomized controlled trial by Temel et al. (2010) demonstrated that patients with metastatic NSCLC receiving early palliative care alongside standard oncologic care had significantly better quality of life (FACT-L score: 98.0 vs. 91.5; p=0.03), less depression (16% vs. 38%; p=0.01), less aggressive end-of-life care (33% vs. 54%; p=0.05), and longer median survival (11.6 vs. 8.9 months; p=0.02) compared to those receiving standard care alone [3].

Subsequent systematic reviews and meta-analyses have confirmed these benefits across multiple cancer types, though the magnitude of effect is most pronounced in lung cancer [9]. The mechanisms proposed include better symptom control, enhanced communication about prognosis and goals, and avoidance of futile interventions.

3.2 Symptom Assessment and Management

3.2.1 Dyspnoea

Dyspnoea affects 70–90% of patients with advanced lung cancer and is often multifactorial: tumour obstruction, pleural effusion, pulmonary embolism, anaemia, infection, or comorbid COPD.

Evidence-Based Management:

· Non-pharmacological interventions: A Cochrane systematic review found moderate-quality evidence that fan therapy, breathing techniques, and energy conservation reduce breathlessness [10].

· Opioids: A Cochrane systematic review of 26 studies concluded that oral or parenteral opioids significantly improve dyspnoea in advanced disease without causing clinically significant respiratory depression [11]. Recommended starting dose: morphine 2.5–5 mg orally every 4 hours as needed, titrated to effect.

· Oxygen: The landmark trial by Abernethy et al. (2010) demonstrated that palliative oxygen is no better than room air for relieving dyspnoea in non-hypoxaemic patients [12]. Oxygen should be reserved for patients with SpO₂ ≤ 90%.

· Benzodiazepines: May be used for associated anxiety, but evidence for direct dyspnoea relief is limited. Use cautiously due to respiratory depression risk [13].

· Pleural interventions: Thoracentesis, talc pleurodesis, or indwelling pleural catheter for malignant pleural effusion (see Section 3.2.4).

3.2.2 Cough

Chronic cough affects 50–80% of lung cancer patients and significantly impairs quality of life.

Evidence-Based Management:

· Opioids: Codeine (30–60 mg every 4–6 hours) or morphine (2.5–5 mg every 4 hours) are effective antitussives [8].

· Corticosteroids: Dexamethasone 4–8 mg daily may reduce tumour-related airway inflammation and improve cough.

· Endobronchial therapies: Laser, cryotherapy, argon plasma coagulation, or stent placement for obstructing endobronchial lesions [14].

· Brachytherapy: Endobronchial brachytherapy provides sustained relief of cough and haemoptysis in selected patients.

3.2.3 Haemoptysis

Haemoptysis occurs in 20–50% of lung cancer patients and is a distressing and potentially life-threatening symptom.

Evidence-Based Management:

· Mild-to-moderate haemoptysis: Palliative external beam radiotherapy (e.g., 20 Gy in 5 fractions or 30 Gy in 10 fractions) is effective for symptom control [8].

· Massive haemoptysis: Bronchial artery embolisation is the first-line intervention for patients who are candidates for active management [15]. Success rates exceed 90% for immediate control.

· Tranexamic acid: May be used as adjunctive therapy; evidence is limited but growing [16].

· Terminal haemoptysis protocol: Have a clear plan in place. Use dark towels to reduce visual distress, position patient on affected side, administer intravenous or subcutaneous midazolam and opioids, and ensure family support.

3.2.4 Malignant Pleural Effusion

Malignant pleural effusion affects 15–40% of lung cancer patients and causes progressive dyspnoea.

Evidence-Based Management:

· Indwelling pleural catheter: The TIME2 trial demonstrated that indwelling pleural catheters provide equivalent dyspnoea relief to talc pleurodesis, with fewer hospital days (median 0 vs. 4 days; p<0.001) [17].

· Talc pleurodesis: Effective when lung re-expands after drainage; success rate 70–80%.

· Thoracentesis: Provides immediate relief and helps assess lung re-expansion. Repeated thoracentesis is not recommended as a long-term strategy.

3.2.5 Pain

Pain affects 40–70% of lung cancer patients and may be nociceptive (chest wall, bone metastases), neuropathic (Pancoast tumour, brachial plexus invasion), or visceral.

Evidence-Based Management:

· WHO analgesic ladder: Start with non-opioids (paracetamol), then weak opioids, then strong opioids [18].

· Adjuvants: Gabapentin or pregabalin for neuropathic pain; corticosteroids for bone pain, nerve compression, and brain metastases.

· Palliative radiotherapy: Single-fraction 8 Gy is as effective as multi-fraction regimens for bone pain (response rate 60–70%) [19].

· Interventional pain management: Intercostal nerve blocks, paravertebral blocks, epidural analgesia, or intrathecal drug delivery for refractory pain.

3.2.6 Superior Vena Cava Syndrome (SVCS)

SVCS occurs in 5–10% of lung cancer patients, particularly SCLC.

Evidence-Based Management:

· Endovascular stenting: Provides rapid relief of facial swelling, headache, and dyspnoea within 24–48 hours [20].

· Radiotherapy: Urgent palliative radiotherapy is effective, especially in NSCLC.

· Corticosteroids: Dexamethasone 8–16 mg daily may reduce tumour oedema, though evidence is limited.

· Chemotherapy: In chemo-sensitive tumours such as SCLC, chemotherapy may relieve obstruction rapidly.

3.2.7 Central Airway Obstruction

Central airway obstruction causes severe dyspnoea, stridor, and respiratory distress.

Evidence-Based Management:

· Bronchoscopic interventions: Laser photoresection, argon plasma coagulation, cryotherapy, and balloon dilatation can rapidly improve airway patency [14].

· Tracheobronchial stents: Silicone or self-expanding metallic stents maintain airway patency for extrinsic compression.

· Brachytherapy: Provides gradual symptom relief for endobronchial tumour.

3.3 Fatigue, Anorexia, and Cachexia

3.3.1 Fatigue

Fatigue affects 80–100% of lung cancer patients and is often multifactorial.

Evidence-Based Management:

· Treat reversible causes: Anaemia (transfusion or iron replacement), infection, dehydration, hypothyroidism, and depression.

· Exercise: A Cochrane systematic review found moderate-quality evidence that aerobic exercise improves fatigue in cancer patients [21].

· Corticosteroids: Dexamethasone 4–8 mg daily may improve energy and wellbeing in advanced disease, but long-term use is limited by side effects.

· Psychostimulants: Methylphenidate may improve fatigue in selected patients; evidence is mixed [22].

3.3.2 Anorexia and Cachexia

Cancer cachexia affects 50–80% of lung cancer patients and is associated with poor prognosis.

Evidence-Based Management:

· Corticosteroids: Dexamethasone 4–8 mg daily improves appetite and wellbeing for short periods.

· Megestrol acetate: Improves appetite but increases thromboembolic risk; use cautiously [23].

· Nutritional counselling: Small, frequent meals; oral nutritional supplements.

· Exercise: Preserves muscle mass and function.

3.4 Psychological and Spiritual Distress

Depression and anxiety affect 30–50% of lung cancer patients and are associated with worse quality of life and outcomes.

Evidence-Based Management:

· Screening: Use PHQ-9, HADS, or Distress Thermometer regularly.

· Pharmacotherapy: SSRIs (sertraline, citalopram, escitalopram) are first-line.

· Psychotherapy: Cognitive behavioural therapy, supportive counselling, and mindfulness.

· Spiritual care: Chaplaincy, meaning-making, legacy work, and cultural rituals.

· Family support: Caregiver burden is high; offer respite and bereavement support.

4. Discussion

4.1 The Importance of Early Integration

The evidence for early palliative care integration in lung cancer is robust and consistent. The Temel trial remains a landmark study demonstrating improved quality of life, mood, and survival [3]. Subsequent trials, including ENABLE III and the Danish PAL trial, have reinforced these findings [24,25]. ASCO and NCCN guidelines now recommend early palliative care referral for all patients with advanced lung cancer [5,6].

Despite this evidence, implementation remains suboptimal. Barriers include physician misconceptions that palliative care is equivalent to end-of-life care, lack of palliative care workforce, and reimbursement challenges. Integrated care models, where palliative care is embedded within oncology clinics, show promise for overcoming these barriers [26].

4.2 Symptom Management Challenges

Dyspnoea remains one of the most challenging symptoms to manage. While opioids are effective, many clinicians under-prescribe due to concerns about respiratory depression. Education and guideline dissemination are essential to improve practice [11].

Haemoptysis, particularly massive haemoptysis, is a distressing emergency. Advanced care planning should include discussion of preferences for intervention versus comfort care. Having a terminal haemoptysis protocol in place is essential for inpatient and hospice settings.

Malignant pleural effusion management has evolved significantly with the introduction of indwelling pleural catheters, which allow home management and reduce hospital days [17]. Patient preference should guide choice of intervention.

4.3 Interventional Palliative Procedures

Interventional pulmonology and interventional radiology play an increasingly important role in palliative lung cancer care. Bronchoscopic interventions for central airway obstruction provide rapid symptom relief and may be life-saving. Endobronchial ultrasound-guided procedures enable minimally invasive diagnosis and palliation.

Interventional radiology contributes through bronchial artery embolisation for haemoptysis, superior vena cava stenting, and image-guided tumour ablation. These procedures should be integrated into a comprehensive palliative care plan.

4.4 Advance Care Planning

The unpredictable trajectory of lung cancer makes advance care planning essential. Discussions should begin early, ideally at the time of diagnosis of advanced disease, and should be revisited at each clinical transition.

Key elements include:

· Goals of care and values.

· Preferences for cardiopulmonary resuscitation and mechanical ventilation.

· Preferences for hospitalisation and intensive care.

· Views on artificial nutrition and hydration.

· Preferred place of care and death.

· Appointment of healthcare proxy.

Research demonstrates that advance care planning improves goal-concordant care, reduces unnecessary hospitalisations, and improves family satisfaction [27].

4.5 End-of-Life Care

Recognising the terminal phase is crucial for providing appropriate end-of-life care. Features suggesting imminent death include:

· Progressive decline in performance status (ECOG ≥3).

· Refractory dyspnoea at rest.

· Worsening anorexia and cachexia.

· Delirium or reduced consciousness.

· Patient expresses desire for comfort-focused care.

Essential medications for end-of-life symptom control:

· Morphine sulfate: 2.5–5 mg subcutaneously every 4 hours as needed for dyspnoea and pain; continuous subcutaneous infusion if frequent doses required.

· Midazolam: 2.5–5 mg subcutaneously every 2–4 hours as needed for agitation or terminal restlessness.

· Glycopyrronium: 0.2–0.4 mg subcutaneously every 6 hours as needed for respiratory secretions.

· Haloperidol: 0.5–1.5 mg subcutaneously every 8 hours as needed for nausea and vomiting.

Discontinuation of non-essential medications: Statins, antihypertensives, and other disease-directed therapies should be discontinued in the terminal phase to reduce treatment burden [28].

4.6 Gaps in Evidence and Future Directions

Despite significant advances, several gaps remain:

· Optimal opioid dosing for dyspnoea in opioid-naïve patients.

· Role of non-invasive ventilation in palliative dyspnoea.

· Effective treatments for cancer cachexia.

· Integration of palliative care in low-resource settings.

· Use of telehealth for palliative care delivery.

Future research should focus on these areas, as well as on implementation science to ensure evidence-based palliative care reaches all patients who need it.

5. Conclusion

Palliative care is an essential component of comprehensive lung cancer management. Early integration improves quality of life, mood, and possibly survival. Effective symptom management requires a multidisciplinary approach, incorporating pharmacological and non-pharmacological interventions, interventional procedures, and comprehensive psychosocial support. Advance care planning should begin early and be revisited regularly. End-of-life care should prioritise comfort, dignity, and family support. Clinicians must be skilled in managing dyspnoea, cough, haemoptysis, pain, and psychological distress, while proactively addressing goals of care.

References

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

2. Cooley ME. Symptoms in adults with lung cancer: a systematic research review. J Pain Symptom Manage. 2000;19(2):137-153. doi:10.1016/s0885-3924(99)00150-5

3. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. doi:10.1056/NEJMoa1000678

4. Temel JS, Greer JA, El-Jawahri A, et al. Effects of early integrated palliative care in patients with lung and GI cancer: a randomized clinical trial. J Clin Oncol. 2017;35(8):834-841. doi:10.1200/JCO.2016.70.5046

5. Ferrell BR, Temel JS, Temin S, et al. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update. J Clin Oncol. 2017;35(1):96-112. doi:10.1200/JCO.2016.70.1474

6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Palliative Care. Version 1.2023. https://www.nccn.org

7. National Institute for Health and Care Excellence. Lung cancer: diagnosis and management. NICE guideline [NG122]. 2019. https://www.nice.org.uk/guidance/ng122

8. Kvale PA, Selecky PA, Prakash UB. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3 Suppl):368S-403S. doi:10.1378/chest.07-1392

9. Kavalieratos D, Corbelli J, Zhang D, et al. Association between palliative care and patient and caregiver outcomes: a systematic review and meta-analysis. JAMA. 2016;316(20):2104-2114. doi:10.1001/jama.2016.16840

10. Bausewein C, Booth S, Gysels M, Higginson IJ. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev. 2008;(2):CD005623. doi:10.1002/14651858.CD005623.pub2

11. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax. 2002;57(11):939-944. doi:10.1136/thorax.57.11.939

12. Abernethy AP, McDonald CF, Frith PA, et al. Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial. Lancet. 2010;376(9743):784-793. doi:10.1016/S0140-6736(10)61115-4

13. Simon ST, Higginson IJ, Booth S, et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev. 2016;10(10):CD007354. doi:10.1002/14651858.CD007354.pub3

14. Guibert N, Mazieres J, Marquette CH, et al. Integration of interventional bronchoscopy in the management of lung cancer. Eur Respir Rev. 2015;24(137):378-391. doi:10.1183/16000617.00004115

15. Chun JY, Morgan R, Belli AM. Radiological management of hemoptysis: a comprehensive review of diagnostic imaging and bronchial arterial embolization. Cardiovasc Intervent Radiol. 2010;33(2):240-250. doi:10.1007/s00270-009-9788-z

16. Prutsky G, Domecq JP, Salazar CA, Accinelli R. Antifibrinolytic therapy to reduce haemoptysis from any cause. Cochrane Database Syst Rev. 2016;11(11):CD008711. doi:10.1002/14651858.CD008711.pub3

17. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on days spent in hospital in patients with malignant pleural effusion: a randomized controlled trial. JAMA. 2012;307(22):2383-2389. doi:10.1001/jama.2012.5535

18. World Health Organization. WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: World Health Organization; 2018.

19. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976. doi:10.1016/j.ijrobp.2010.11.026

20. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. Clin Oncol (R Coll Radiol). 2002;14(5):338-351. doi:10.1053/clon.2002.0109

21. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012;11(11):CD006145. doi:10.1002/14651858.CD006145.pub3

22. Minton O, Richardson A, Sharpe M, et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;(7):CD006704. doi:10.1002/14651858.CD006704.pub3

23. Ruiz Garcia V, López-Briz E, Carbonell Sanchis R, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;(3):CD004310. doi:10.1002/14651858.CD004310.pub3

24. Bakitas MA, Tosteson TD, Li Z, et al. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol. 2015;33(13):1438-1445. doi:10.1200/JCO.2014.58.6362

25. Groenvold M, Petersen MA, Damkier A, et al. Randomised clinical trial of early specialist palliative care plus standard care versus standard care alone in patients with advanced cancer: the Danish Palliative Care Trial. Palliat Med. 2017;31(9):814-824. doi:10.1177/0269216317705100

26. Hui D, Kim SH, Roquemore J, et al. Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer. 2014;120(11):1743-1749. doi:10.1002/cncr.28628

27. Brinkman-Stoppelenburg A, Rietjens JA, van der Heide A. The effects of advance care planning on end-of-life care: a systematic review. Palliat Med. 2014;28(8):1000-1025. doi:10.1177/0269216314526272

28. Kutner JS, Blatchford PJ, Taylor DH Jr, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175(5):691-700. doi:10.1001/jamainternmed.2015.0289

Prepared By: Dr. Shekhar and Team, Doctor's Forum for All 🏥

Date: 2026